KITOV PHARMA LT/S (NASDAQ:KTOV) has been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Brokerages have set a 12 month consensus price target of $12.00 for the company and are forecasting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also given KITOV PHARMA LT/S an industry rank of 69 out of 256 based on the ratings given to related companies.
Separately, ValuEngine raised KITOV PHARMA LT/S from a “sell” rating to a “hold” rating in a report on Monday, May 20th.
KTOV stock traded up $0.02 during trading hours on Friday, hitting $0.82. 948 shares of the stock traded hands, compared to its average volume of 367,967. The stock has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $0.98. KITOV PHARMA LT/S has a one year low of $0.56 and a one year high of $2.92. The company has a market cap of $12.86 million, a P/E ratio of 2.15 and a beta of 3.61. The company has a current ratio of 1.99, a quick ratio of 2.57 and a debt-to-equity ratio of 0.01.
About KITOV PHARMA LT/S
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study.
Featured Story: Arbitrage
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KITOV PHARMA LT/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KITOV PHARMA LT/S and related companies with MarketBeat.com's FREE daily email newsletter.